Cloudbreak Pharma Announces Results of First-of-Its-Kind Patient Survey on Pinguecula, Confirming Significant Unmet Need and Impact on Quality of Life (opens original article in a new tab)

Cloudbreak Pharma announced results from a patient survey on pinguecula, highlighting significant unmet need and patient interest in a new treatment, with their drug CBT-004 entering Phase 3 trials.

• Cloudbreak Pharma conducted a survey of 1,020 U.S. adults, finding that 10% had pinguecula and 75% found it moderately to greatly bothersome.
• The survey showed patients expressed moderate-to-great interest in a prescription treatment for pinguecula, as no FDA-approved options exist.
• Cloudbreak Pharma's CBT-004, a VEGF inhibitor, is in Phase 3 trials for pinguecula, with potential to be the first FDA-approved treatment for the condition.